Patent intelligence · US
US 12209073
Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
Patent details — US 12209073
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 28, 2025
- Expiration
- Jan 23, 2045
- Applicant
- KIORA PHARMACEUTICALS GmbH
- Claims
- 20
- CPC classes
- A61P, A61P29/00, A61P35/00
Quick answer
US 12209073 (Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor) is held by KIORA PHARMACEUTICALS GmbH. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KIORA PHARMACEUTICALS GmbH
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P29/00, A61P35/00
More from KIORA PHARMACEUTICALS GmbH
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12209073?
US 12209073 (Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor) is held by KIORA PHARMACEUTICALS GmbH. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12209073?
KIORA PHARMACEUTICALS GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12209073 expire?
Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.